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Human	specific	models	for	studying	ER + ve	and	ER-ve	breast	cancer	bone	metastasis	
Diane	Lefley,	Faith	Nutter,	Hannah	Brow,	Claudia	Tulotta,	Rachel	Eyre,	Robert	Clarke,	Denis	Alferez,	
Mark	Wilkinson,	Ingunn	Holen,	Penelope	Ottewell	
Background:	Bone	metastasis	is	commonly	modelled	using	xenograft	transplantation	in	
immunocompromised	mice	and	are	limited	by	the	lack	of	a	true	metastatic	pathway.	It	is	also	likely	
that	there	are	species-specific	differences	involved	in	growing	human	cells	in	a	murine	environment.	
We	have	developed	models	where	human	breast	cancer	cells	metastasise	to	human	bone	in	mice.	
Methods:	Bone	discs	from	femoral	heads	of	patients	undergoing	hip	replacement	surgery	were	
implanted	subcutaneously	into	NOD/SCID	mice.	For	metastasis	studies	PDX	(BB3RC32,	
ER + PR + HER2-;	BB2RC08,	ER + PR-ER2-;	BB6RC37,	ER-PR-HER2-	and	BB6RC39,	ER + PR + HER2+),	
MDA-MB-231-luc2	or	T47D-luc2	cells	were	injected	directly	into	human	bone	implants	or	into	
mammary	fat	pads	and	metastases	detected	by	luciferase	imaging.	Bone	discs	were	harvested	
weekly	for	4	weeks,	osteoblast	viability	measured	by	calcein	uptake	and	bone	integrity	assessed	by	
uCT.	Osteoclasts/osteoblasts	and	blood	vessels	were	identified	following	TRAP	and	CD31	staining.	
	
Results:	Following	implantation	of	subchondral	bone,	MDA-MB-231	cells	metastasised	from	
mammary	fat	pads	to	the	human	bone	discs	in	70%	of	mice	within	6–8	weeks	and	T47D	cells	in	60%	
of	mice	within	8–10	weeks.	Following	implantation	of	spongy	bone,	metastasis	occurred	in	~ 28%	of	
animals	12–16	weeks	after	injection	of	either	cell	line.	Interestingly,	MDA-MB-231	cells	specifically	
metastasised	to	the	human	bone	implants	whereas	T47D	cells	BB3RC32,	BB2RC08,	and	BB6RC37	
metastasised	to	both	human	bone	and	mouse	long	bones.	Analysis	of	bone	implants	in	the	absence	
of	tumours	showed	re-vascularisation	by	both	human	and	mouse	endothelial	cells.	No	change	in	
bone	volume	was	detected,	however,	osteocyte	viability	was	reduced	to	40%	of	control	by	day	7	
(p < 0.0001)	and	then	stabilised.	Osteoblast	activity	was	confirmed	by	active	calcein	uptake	from	day	
21	and	presence	of	osteoclasts	on	the	bone	surface	increased	with	time.	
	
Conclusions:	In	vivo	implantation	of	human	bone	discs	provides	a	species-specific	metastatic	site	for	
breast	cancer	cells.	
